Ramsay Health Care Signals Fall in Annual Profit From Continuing Operations
By David Winning
SYDNEY--Private hospital operator Ramsay Health Care said writedowns and impairment charges against some of its European businesses would weigh on its fiscal 2024 net profit.
Ramsay Health Care said it expects a net profit from continuing operations of between 265 million Australian dollars (US$172.5 million) and A$270 million in the 12 months through June. That suggests a lower result than the A$278.2 million profit achieved in the 2023 fiscal year.
Statutory profit is likely to be in a range of A$884 million to A$889 million as it includes the A$618 million gain on sale of the Ramsay Sime Darby venture, Ramsay said.
In Monday's regulatory filing, Ramsay signaled non-cash impairments and accelerated writedowns "against the book value of underperforming assets in both Ramsay Santé and the U.K. region" of A$24.5 million.
Still, Ramsay said it is benefiting from improving activity trends and labor productivity, while capital expenditure in fiscal 2024 was less than forecast at around A$740 million, driven by an unexpectedly low level of spending in Australia.
Ramsay is due to confirm its fiscal 2024 result and comment on the outlook for the current year on Aug. 30.
Write to David Winning at david.winning@wsj.com
(END) Dow Jones Newswires
August 04, 2024 19:16 ET (23:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk